Dicerna Pharmaceuticals to sell 2.75 million common shares to public

Jefferies, Leerink Partners, Cowen, Stifel help fund studies, trials

By Devika Patel

Knoxville, Tenn., May 19 – Dicerna Pharmaceuticals Inc. will sell 2.75 million common shares in a public sale with a 30-day greenshoe of 420,000 additional shares, according to a preliminary prospectus supplement filed Tuesday with the Securities and Exchange Commission.

Jefferies, Leerink Partners and Cowen and Co. are the bookrunners; Stifel is the lead manager.

Proceeds will be used for preclinical studies and clinical trials, technology platform development, working capital and general corporate purposes, including acquisitions or investments.

The biopharmaceutical company is based in Watertown, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.